Adamax

Research summary

Adamax is marketed by research-peptide suppliers as a modified analog of Semax, with an adamantane group added to the backbone to improve resistance to enzymatic breakdown and blood-brain-barrier penetration. The rationale draws on Semax's own study history in neurotrophic and cognitive research.

No independent, peer-reviewed studies evaluating Adamax by name were identified in the published literature; available information comes from research-chemical vendor documentation rather than academic sources. Published research on the parent compound Semax has examined cognitive and neuroprotective effects in animal and limited human studies, but those findings have not been independently confirmed for this adamantane-modified analog.

Sources: Vendor technical documentation; no peer-reviewed primary literature identified as of October 2026. Findings from published research —not a claim about this product, and not evidence of safety or effectiveness for human use.